News

Abbott has opened a new Nutrition facility at the Research Park on the University of Illinois campus. The company will use the facility to research and develop nutritional

Exelixis and Bristol-Myers Squibb have reported updated phase 2 clinical data, which demonstrates XL184 activity in patients with glioblastoma multiforme (GBM). XL184 (BMS-907351) is an investigational oral inhibitor

Lonza has announced that it has signed an investment agreement, including a right of first refusal for the commercial production of products, with Cilian. The collaboration with Cilian

Biomoda has entered into a final stage of patient testing in the phase II clinical trial of it’s early-stage diagnostic for lung cancer. The next stage of the

Medgenics has signed a preclinical development and option agreement with an international biopharmaceutical company. The agreement is worth up to $7m in payments that will include funding for

MPI Research has announced that it will be collaborating with Kineta. MPI Research will assist Kineta with advancing their autoimmune drug development program. The company said that the

Camfil Farr has been working closely with the capital projects team at Pfizer global research and development to help them realise significant savings on existing HVAC plant serving

The European Commission has granted marketing authorisation to Novartis for its Exforge HCT, a new 3-in-1 treatment for people with high blood pressure. Exforge HCT combines the efficacy

Aldevron has announced that the company is expanding into Madison, WI. The new division will produce and sell contract research and manufacturing services marketed under the Aldevron brand.